Equities Analysts Offer Predictions for PVLA FY2028 Earnings

Key Points

• HC Wainwright has upgraded its FY2028 earnings per share estimate for Palvella Therapeutics to ($2.62) from ($3.15) and maintains a "Buy" rating with a price target of $95.00.
• The consensus estimate for Palvella Therapeutics' current full-year earnings is ($3.69) per share, and the stock is currently valued at around $59.59.
• Palvella Therapeutics has received multiple positive ratings from analysts, with one issuing a Strong Buy rating and several others setting price targets ranging from $56.00 to $90.00.

Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) - Investment analysts at HC Wainwright lifted their FY2028 earnings per share (EPS) estimates for shares of Palvella Therapeutics in a note issued to investors on Thursday, September 25th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($2.62) per share for the year, up from their previous forecast of ($3.15). HC Wainwright has a "Buy" rating and a $95.00 price target on the stock. The consensus estimate for Palvella Therapeutics' current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for Palvella Therapeutics' FY2029 earnings at ($0.58) EPS.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.78) by ($0.08).

Several other research analysts have also recently issued reports on PVLA. Oppenheimer started coverage on Palvella Therapeutics in a research report on Tuesday, September 9th. They set an "outperform" rating and a $85.00 price objective for the company. Canaccord Genuity Group upped their price objective on Palvella Therapeutics from $52.00 to $66.00 and gave the stock a "buy" rating in a research report on Tuesday, August 19th. Lifesci Capital started coverage on Palvella Therapeutics in a research report on Monday, August 4th. They set an "outperform" rating and a $90.00 price objective for the company. Stifel Nicolaus upped their price objective on Palvella Therapeutics from $60.00 to $80.00 and gave the stock a "buy" rating in a research report on Wednesday, September 24th. Finally, Truist Financial started coverage on Palvella Therapeutics in a research report on Monday, July 21st. They set a "buy" rating and a $56.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating and eleven have issued a Buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $67.09.

Palvella Therapeutics Stock Performance

NASDAQ:PVLA opened at $59.59 on Monday. The stock has a 50-day simple moving average of $48.78 and a 200-day simple moving average of $32.91. The stock has a market cap of $659.07 million, a P/E ratio of -4.92 and a beta of -0.04. Palvella Therapeutics has a 1 year low of $11.17 and a 1 year high of $63.12.

Institutional Trading of Palvella Therapeutics

A number of large investors have recently made changes to their positions in PVLA. Millennium Management LLC acquired a new stake in shares of Palvella Therapeutics in the 1st quarter valued at about $7,553,000. Woodline Partners LP purchased a new stake in Palvella Therapeutics during the 1st quarter valued at approximately $5,435,000. Clio Asset Management LLC purchased a new stake in Palvella Therapeutics during the 2nd quarter valued at approximately $2,063,000. Geode Capital Management LLC raised its stake in Palvella Therapeutics by 84.7% during the 2nd quarter. Geode Capital Management LLC now owns 173,986 shares of the company's stock valued at $3,923,000 after acquiring an additional 79,787 shares during the last quarter. Finally, Royce & Associates LP purchased a new stake in Palvella Therapeutics during the 1st quarter valued at approximately $2,002,000. 40.11% of the stock is owned by institutional investors and hedge funds.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.